Replimune Group Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
38.6%projected annual EPS growth
Analyst Coverage
6analysts covering
FY Revenue (est.)
$50.2Mnext fiscal year
FY EPS (est.)
-$2.75next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Short-Term Investments Quarterly269.1MTarget: Sufficient capital to fund operations late into the first quarter of calendar 2027
IGNYTE-3 Phase 3 Trial Enrollment QuarterlyTarget: Enroll approximately 400 patients globally
RP1 Biologics License Application (BLA) Status QuarterlyTarget: Successful resubmission and FDA prioritization of review
Watch Items
- RP1 BLA Resubmission and FDA Review TimelineTrigger: Resubmission of the BLA following alignment with the FDA on a path forwardAction: Monitor regulatory filings and press releases for the official resubmission date and subsequent FDA action/review timeline.
- IGNYTE-3 Confirmatory Phase 3 Trial ProgressTrigger: Execution of descriptive analysis supporting contribution of componentsAction: Track clinical trial registry updates and corporate presentations for enrollment milestones and overall survival (OS) primary endpoint data.
- RP2 Clinical Development in Solid TumorsTrigger: Transition of RP2 combined with nivolumab into randomized Phase 2/3 trial in metastatic uveal melanomaAction: Evaluate clinical updates from the REVEAL trial and monotherapy data in hepatocellular carcinoma (HCC) expected by the end of 2026.
Research as of 19 Jun 2026